Article Text

Download PDFPDF
The influence of frailty under direct oral anticoagulant use in patients with atrial fibrillation
  1. Takashi Yamamoto1,
  2. Kentaro Yamashita1,
  3. Kiichi Miyamae1,
  4. Yuichiro Koyama1,
  5. Masataka Izumimoto1,
  6. Yoshihiro Kamimura1,
  7. Satoko Hayakawa1,
  8. Kazutaka Mori1,
  9. Takaaki Yamada1,
  10. Yasushi Tomita1,
  11. Toyoaki Murohara2
  1. 1Department of Cardiology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan
  2. 2Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan
  1. Correspondence to Dr Kentaro Yamashita, Cardiology, National Hospital Organization Nagoya Medical Center, Nagoya 460-0001, Japan; yamaken2929{at}gmail.com

Abstract

Background Frailty is a prognostic factor in patients with atrial fibrillation (AF). However, there is no report on the associations between frailty and clinical adverse events in patients with AF taking direct oral anticoagulants (DOAC). The factors related to the occurrence of clinical adverse events are still under discussion. Therefore, we examined the associations between frailty and clinical adverse events in patients with AF taking DOAC in daily clinical practice.

Methods We retrospectively evaluated 240 consecutive patients with AF who had been newly prescribed DOAC in our hospital from April 2016 through May 2017. Data collected included Clinical Frailty Scale (CFS) scores, laboratory results and basic demographic information.

Results During the mean follow-up period of 13.4 months, 20 patients died (7.6 per 100 person-years), stroke or systemic embolism occurred in seven patients (2.6 per 100 person-years) and major bleeding occurred in 11 patients (4.2 per 100 person-years). We defined these adverse events as composite end points, and we estimated adjusted HRs and 95% CIs for risk factors using the Cox proportional hazard regression model. Frailty (defined as a CFS score of 5 or more; HR: 3.71; 95% CI: 1.59 to 8.65), female sex (HR: 3.49; 95% CI: 1.73 to 7.07), serum albumin level (HR: 0.47; 95% CI: 0.28 to 0.79) and malignancy (HR: 4.02; 95% CI: 1.83 to 8.84) were independent predictors of the composite end points.

Conclusions Frailty, female sex, hypoalbuminaemia and malignancy were associated with clinical adverse events in patients with AF who were prescribed DOAC.

  • atrial fibrillation
  • direct oral anticoagulants
  • frailty
View Full Text

Statistics from Altmetric.com

Footnotes

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.